Selective elimination of early pathological TAU species may be a promising therapeutic strategy to reduce the accumulation of TAU, which contributes to neurodegeneration and is a hallmark of Alzheimer's disease (AD). Pathological hyper-phosphorylated TAU can be degraded through selective autophagy, and NDP52/CALCOCO2 is one of the autophagy receptors involved in this process. In 2021, we discovered a variant of NDP52, called NDP52(GE) (rs550510), that is more efficient at promoting autophagy. We here anticipate that this variant could be a powerful factor that could eliminate pathological forms of TAU better than its WT form (NDP52(WT)). Indeed, we provide evidence that in in vitro systems and in a Drosophila melanogaster model of TAU-induced AD, the NDP52(GE) variant is much more effective than the NDP52(WT) in reducing the accumulation of pathological forms of TAU through the autophagic process and rescues typical neurodegenerative phenotypes induced by hTAU toxicity. Mechanistically, we showed that NDP52(WT) and NDP52(GE) bind pTAU with comparable efficiency, but that NDP52(GE) binds the autophagic machinery (LC3C and LC3B) more efficiently than NDP52(WT) does, which could explain its greater efficiency in removing pTAU. Finally, by performing a genetic analysis of a cohort of 435 AD patients, we defined the NDP52(GE) variant as a protective factor for AD. Overall, our work highlights the variant NDP52(GE) as a resilience factor in AD that shows a robust effectiveness in driving pathological TAU degradation.